Nanosonics Limited ( (AU:NAN) ) just unveiled an update.
Nanosonics Limited has received FDA De Novo clearance for its CORIS® system, a novel technology aimed at reducing infection risks and improving cleaning outcomes for flexible endoscopes. This clearance marks a significant milestone for the company, with plans for a commercial launch in Q1 FY26, initially targeting a controlled market release in select hospitals before a broader rollout.
More about Nanosonics Limited
Nanosonics Limited is a leader in infection prevention solutions, focusing on innovative technologies to improve cleaning outcomes for medical devices, particularly flexible endoscopes. The company is dedicated to enhancing patient safety and addressing critical challenges in medical device reprocessing.
YTD Price Performance: 49.73%
Average Trading Volume: 833
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $849.7M
For a thorough assessment of NAN stock, go to TipRanks’ Stock Analysis page.